Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

2.30
+0.12005.50%
Post-market: 2.28-0.0200-0.87%19:30 EDT
Volume:3.19M
Turnover:7.30M
Market Cap:1.02B
PE:-14.49
High:2.31
Open:2.19
Low:2.19
Close:2.18
52wk High:2.68
52wk Low:1.03
Shares:444.00M
Float Shares:220.42M
Volume Ratio:1.09
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1587
EPS(LYR):-0.1387
ROE:-40.21%
ROA:-14.32%
PB:5.85
PE(LYR):-16.59

Loading ...

Lexicon says Phase 2b data support pilavapadin 10 mg for Phase 3 DPNP trial

Reuters
·
Apr 17

Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026

Reuters
·
Mar 24

Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 23

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
Mar 23

Lexicon, Novo Nordisk announce initiation of LX9851 study

TIPRANKS
·
Mar 23

Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851

Reuters
·
Mar 23

Lexicon Pharmaceuticals Inc - Phase 1 Study of Lx9851 Expected to Complete in Q1 2027

THOMSON REUTERS
·
Mar 23

Lexicon Pharmaceuticals and Novo Nordisk Announce Initiation of Phase 1 Study With Oral Obesity Drug Candidate Lx9851

THOMSON REUTERS
·
Mar 23

Lexicon Pharmaceuticals Inc - Earns Second $10 Mln Milestone; Eligible for up to $1 Bln in Payments

THOMSON REUTERS
·
Mar 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)

TIPRANKS
·
Mar 13

Lexicon announces results from post hoc analysis on data of sotagliflozin

TIPRANKS
·
Mar 11

Lexicon to present sotagliflozin kidney function analysis at ATTD conference

Reuters
·
Mar 11

Lexicon Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 10

Lexicon price target raised to $2.30 from $2.10 at Citi

TIPRANKS
·
Mar 10

Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones

TIPRANKS
·
Mar 10

Leerink Partners Sticks to Its Hold Rating for Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
Mar 06

Lexicon Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 06

Lexicon price target raised to $6 from $4 at H.C. Wainwright

TIPRANKS
·
Mar 06

Lexicon Pharmaceuticals Q4 net loss narrows on lower R&D spend

Reuters
·
Mar 05

Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate

Benzinga Earnings
·
Mar 05